Abstract
2018 ASHP Midyear Clinical Meeting / Anaheim, California / Poster # 11-309
Objective: Evaluate bleeding and thrombotic risk of patients receiving triple antithrombotic therapy (TAT) versus dual antithrombotic therapy (DAT) and characterize prescribing patterns.
Document Type
Article
Publication Date
2018
Recommended Citation
Lundy, Katharine PharmD; Meisberger, Elizabeth PharmD, BCPS; Howard, Kris PharmD, BCPS, AACC; and Sposito, Jennifer PharmD, "Evaluation of bleeding and thrombotic risk in patients receiving triple antithrombotic therapy" (2018). Parkview Pharmacy Department. 30.
https://researchrepository.parkviewhealth.org/pharma/30
